Advances in the study of the nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in Parkinson′s disease
10.3760/cma.j.issn.1006-7876.2020.02.014
- VernacularTitle: 核苷酸结合寡聚化结构域样受体蛋白3炎性小体在帕金森病中的研究进展
- Author:
Zhanyu ZHANG
1
;
Yan LI
2
;
Yuhu ZHANG
1
Author Information
1. School of Medicine, South China University of Technology, Guangzhou 510006, China; Department of Neurology, Guangdong Provincial People′s Hospital, Guangdong Academy of Medical Sciences, Guangdong Neuroscience Institute, Guangzhou 510080, China
2. Department of Neurology, Guangdong Provincial People′s Hospital, Guangdong Academy of Medical Sciences, Guangdong Neuroscience Institute, Guangzhou 510080, China
- Publication Type:Review
- Keywords:
Parkinson disease;
Caspase 1;
Inflammation;
Nucleotide-binding oligomerization domain-like receptor protein 3
- From:
Chinese Journal of Neurology
2020;53(2):147-151
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson′s disease (PD) is a common neurodegenerative disorder characterized by progressive loss of dopaminergic neurons of the substantia nigra. While the etiology of PD is likely multifactorial, and the neuroinflammation is a significant component to the pathogenesis of the disease. The nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasomes are multiprotein innate immune complexes regulating inflammation. In the neuroinflammation of PD, the assembly of NLRP3 inflammasome complexes could recruit and activate the caspase-1. Activated caspase-1 cleaves the precursors of interleukin-1β as well as interleukin-18 to produce the downstream inflammatory cascade damaging the dopaminergic neuron. This review provides an overview of the recent studies concerning NLRP3 inflammasome in the pathophysiology of PD, and discusses potential therapeutic strategies to alleviate the progression of PD by inhibiting NLRP3 inflammasome.
